Evidence map›Paper›PMID 31100090›Full record

ArticlePloS one2019

Protective effects of urocortin 2 against caerulein-induced acute pancreatitis.

Jingzhen Yuan, Burcu Hasdemir, Tanya Tan, Chintan Chheda, Jean Rivier, Stephen J Pandol, Aditi Bhargava

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jingzhen YuanCedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Burcu HasdemirThe Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
Tanya TanVeterans Affairs Greater Los Angeles Healthcare System, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America.
Chintan ChhedaCedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Jean RivierThe Salk Institute, The Clayton Foundation Laboratories for Peptide Biology, La Jolla, CA, United States of America.
Stephen J PandolCedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Aditi BhargavaThe Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, United States of America.ORCID 0000-0003-1334-0517
Cedars-Sinai Medical Center · USUniversity of California, San Francisco · USSalk Institute for Biological Studies · USUniversity of California, Los Angeles · US

Funding

The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
Vector and Human Acinar CoreP01DK098108 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PANDOL, STEPHEN J. · 2014 to 2018
$8.1M
Targeting protein kinase D in alcoholic pancreatitisR01AA024464 · NIAAA · CEDARS-SINAI MEDICAL CENTER · PI PANDOL, STEPHEN J., YUAN, JINGZHEN · 2016 to 2020
$2.0M
Neuroplasticity of the gut-brain axis in functional dyspepsiaR01DK097518 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BHARGAVA, ADITI, PASRICHA, PANKAJ J · 2014 to 2016
$1.6M
Regulation and Function of Urocortins and their ReceptorR56DK080787 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BHARGAVA, ADITI · 2015 to 2015
$341k
NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA024464NIDDK NIH HHS P01 DK098108NIDDK NIH HHS R01 DK097518NIDDK NIH HHS R56 DK080787
6 · The paper itself

Abstract

Because little is known about the role of corticotropin-releasing factor (CRF) agonists in regulating responses in pancreatitis, we evaluated the effects of urocortin 2 (UCN2) and stressin1 in caerulein-induced acute pancreatitis (AP) model in rats. Male rats were pretreated with UCN2 or stressin1 for 30 min followed by induction of AP with supraphysiologic doses of caerulein. Serum amylase and lipase activity, pancreatic tissue necrosis, immune cell infiltrate, nuclear factor (NF)-κB activity, trypsin levels, and intracellular Ca2+ ([Ca2+]i) were ascertained. UCN2, but not stressin1 attenuated the severity of AP in rats. UCN2, but not stressin1, reduced serum amylase and lipase activity, cell necrosis and inflammatory cell infiltration in AP. NF-κB activity in pancreatic nuclear extracts increased in AP and UCN2 treatment reduced caerulein-induced increases in NF-κB activity by 42%. UCN2 treatment prevented caerulein-induced degradation of IκB-α in the cytosolic fraction as well as increased levels of p65 subunit of NF-κB in the cytosolic fraction. Pancreatic UCN2 levels decreased in AP compared with saline. UCN2 evoked [Ca2+]i responses in primary acinar cells and abolished caerulein-evoked [Ca2+]i responses at 0.1nM, and decreased by ~50% at 1.0nM caerulein. UCN2 stimulation resulted in redistribution of a portion of F-actin from the apical to the basolateral pole. UCN2 prevented the massive redistribution of F-actin observed with supraphysiologic doses of caerulein. UCN2, but not stressin1 attenuated severity of an experimental pancreatitis model. The protective effects of UCN2, including anti-inflammatory and anti-necrotic effects involve activation of the CRF2 receptor, [Ca2+]i signaling, and inhibition of NF-κB activity.

Indexed as

Acinar CellsAnimalsCeruletideCorticotropin-Releasing HormoneMaleNF-kappa BNF-KappaB Inhibitor alphaPancreatitisRatsRats, Sprague-DawleySignal TransductionUrocortinsCeruletideCorticotropin-Releasing HormoneNF-kappa BNF-KappaB Inhibitor alphaurocortin 3, ratUrocortins

Identifiers

PMID31100090
PMCPMC6524941
OpenAlexW2946451402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.